Fully biologically active when compared to standard. The ED50 determined by a chemotaxis bioassay using human peripheral blood T-lymphocytes is less than 100 ng/ml, corresponding to a specific activity of >, 1.0 × 104 IU/mg.
纯度
> 97 % by SDS-PAGE and HPLC analyses.
内毒素水平
Level Less than 1EU/µg of rHuMIG/CXCL9 as determined by LAL method
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 °C. Further dilutions should be made in appropriate buffered solutions.
CXCL9, a member of the ª subfamily of chemokines that lack the ELR domain, was initially identified as a lymphokine-activated gene in mouse macrophages. The CXCL9 gene is induced in macrophages and in primary glial cells of the central nervous system specifically in response to IFN-γ. CXCL9 has been shown to be a chemoattractant for activated T-lymphocytes and TIL but not for neutrophils or monocytes. The human CXCL9 cDNA encodes a 125 amino acid residue precursor protein with a 22 amino acid residue signal peptide that is cleaved to yield a 103 amino acid residue mature protein. CXCL9 has an extended carboxy-terminus containing greater than 50% basic amino acid residues and is larger than most other chemokines. A chemokine receptor (CXCR3) specific for CXCL9 and IP-10 has recently been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes. Synonym: MIG/CXCL9, Human. Formulation: Lyophilized from a 0.2µm filtered concentrated solution in 20mM PB, pH 7.4, 50mM NaCl.
分子量
11.7 kDa, a single non-glycosylated polypeptide chain containing 103 amino acids.